YOUNG WILLIAM D 4

What Happened
William D. Young, a director of Praxis Precision Medicines (PRAX), received two equity awards on June 10, 2026: 1,371 restricted stock units (RSUs) and 648 derivative units. Both grants were non-cash awards reported at $0.00 per share (standard for RSU/derivative awards); no shares were sold. These are compensation awards, not open-market purchases or sales.

Key Details

• Transaction date: 2026-06-10; Form 4 filed 2026-06-12 (timely filing).
• Awards: 1,371 RSUs (reported as A, $0.00) and 648 derivative units (reported as A, $0.00).
• Shares owned after transaction: not specified in the filing.
• Footnote highlights:
  • The 1,371 RSUs convert to one share each and vest in a single installment on the earlier of June 10, 2027 or the issuer’s 2027 annual meeting. (F1)
  • The 648 derivative award vests in 12 equal monthly installments starting July 10, 2026, through June 10, 2027 (or earlier if the 2027 meeting occurs). (F2)
• No indication of tax-withholding sale, 10b5-1 plan, or late filing.

Context

• RSUs and derivative awards are non-cash director compensation that will convert to common stock as they vest; they do not by themselves indicate buying or selling intent.
• The derivative award’s monthly vesting means shares will be delivered over roughly a one-year period if vesting conditions are met.
• For retail investors, director grants are routine corporate governance/compensation events; track future Form 4 filings for any sales or additional disclosures.